MedPath

Tagged News

1Cell.Ai Launches OncoIncytes: Revolutionary Multi-Modal Cancer Diagnostic Panel for Precision Oncology

AIOncology
  • 1Cell.Ai (formerly OneCell Diagnostics) has launched OncoIncytes, a comprehensive multi-modal cancer diagnostic panel that integrates ctDNA, CTCs, RNA transcriptomics, and proteomics data for enhanced precision oncology.
  • The technology employs a 1080 gene panel with AI and machine learning models, offering unprecedented sensitivity to optimize clinical trials, particularly for antibody-drug conjugate development.
  • Following a $16M Series A funding round, the company's rebranding reflects its evolution from genomics-based diagnostics to AI-powered precision oncology solutions aimed at revolutionizing cancer care.

Guardant Health's Shield Multi-Cancer Detection Test Shows Strong Performance Across 10 Cancer Types

Oncology
  • Guardant Health's blood-based Shield Multi-Cancer Detection test demonstrated 98.5% specificity and 60% overall sensitivity across ten tumor types, with particularly strong results for aggressive cancers.
  • The test achieved 89% accuracy for cancer signal of origin prediction, potentially enabling clinicians to identify the primary tumor location through a simple blood draw.
  • Based on these promising results, the National Cancer Institute selected Shield MCD for its upcoming Vanguard Study evaluating emerging multi-cancer detection technologies.

Personalis to Present New Data on NeXT Personal ctDNA Test for Early Cancer Detection at Major Oncology Conferences

Oncology
  • Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types.
  • The VICTORI study will present preliminary results on post-surgical minimal residual disease detection in colorectal cancer, while the TRACERx collaboration will share findings from one of the largest ctDNA studies in early-stage lung cancer.
  • New research will expand clinical evidence for NeXT Personal into neoadjuvant treatment settings for breast cancer and cervical cancer, supporting the company's mission to enable earlier detection of residual and recurrent cancer.

VCU Massey Becomes First Virginia Center to Offer Robotic HIFU for Prostate Cancer Treatment

Oncology
  • VCU Massey Comprehensive Cancer Center has become the first institution in Virginia to offer robotic high-intensity focused ultrasound (HIFU) using the Focal One system for prostate cancer treatment.
  • The noninvasive procedure takes approximately one to one-and-a-half hours and allows patients to return home the same day while preserving key structures related to erectile function and continence.
  • HIFU offers a less morbid alternative to surgery and radiation for intermediate-risk prostate cancer patients, with studies showing about 25% may need repeat ablation and 20-30% may progress to surgery or radiation within five years.
  • The technology addresses a significant clinical gap for patients with prostate cancer that is not aggressive enough for active surveillance but not severe enough to warrant immediate radical treatment.

Cemiplimab Shows Significant Survival Benefit in NSCLC Patients with Brain Metastases and High PD-L1 Expression

Monoclonal AntibodyDrug ApprovalOncology
  • First-line cemiplimab (Libtayo) monotherapy demonstrated a remarkable survival advantage over chemotherapy in advanced NSCLC patients with PD-L1 ≥50% and brain metastases, with median OS of 52.4 vs 20.7 months.
  • The EMPOWER-Lung 1 trial's 5-year follow-up data confirms cemiplimab's long-term clinical benefits across all PD-L1 expression levels, with the greatest benefit observed in patients with PD-L1 ≥90%.
  • Patients receiving cemiplimab experienced fewer grade ≥3 adverse events compared to chemotherapy (18.3% vs 39.9%), while also reporting improved quality of life measures including better emotional functioning and reduced fatigue.

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

NCT03789604Active, Not RecruitingPhase 3
CStone Pharmaceuticals
Posted 12/13/2018

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03088540CompletedPhase 3
Regeneron Pharmaceuticals
Posted 5/29/2017

Nusano Secures Major Supply Agreements with Ratio Therapeutics and Clarity Pharmaceuticals to Address Critical Radioisotope Shortage

Oncology
  • Nusano has entered into long-term supply agreements with Ratio Therapeutics and Clarity Pharmaceuticals to provide critical radioisotopes including copper-64, lutetium-177, and actinium-225 for cancer diagnostics and therapeutics.
  • The agreements address significant supply constraints in the radiopharmaceutical market, with Nusano's proprietary platform capable of producing over 1,000 curies of copper-64 daily from its upcoming Utah facility.
  • These partnerships position both pharmaceutical companies to advance their clinical pipelines, with Clarity's SAR-bisPSMA diagnostic ready for commercial rollout and Ratio's FAP-targeted radiotherapy entering clinical trials this year.

Balancing Efficacy and Cost Sustainability in Modern CLL Treatment: Insights from Dr. Pierluigi Porcu

Oncology
  • Clinicians treating chronic lymphocytic leukemia (CLL) face growing challenges in balancing clinical efficacy with long-term cost sustainability, requiring a holistic approach to patient care.
  • Dr. Pierluigi Porcu emphasizes that effective CLL management requires understanding disease risk, patient comorbidities, and practice environment constraints including payer considerations.
  • Despite its importance, value-based care adoption remains insufficient in oncology, with challenges in defining and measuring value across patient outcomes, quality of life, and treatment costs.

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Active, Not RecruitingPhase 3
Acerta Pharma BV
Posted 2/25/2019

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603Active, Not RecruitingPhase 3
Stichting European Myeloma Network
Posted 12/14/2018

Alcohol-Related Deaths and Cancer Fatalities Surge in U.S. Over Past Two Decades

Oncology
  • Alcohol-related deaths in the United States nearly doubled from 1999 to 2020, rising from 10.7 to 21.6 per 100,000 people, with women experiencing the largest relative increase despite men having higher overall rates.
  • Cancer deaths linked to alcohol consumption doubled between 1990 and 2021, increasing from approximately 12,000 to over 23,000 annual deaths, with men accounting for 70% of these fatalities.
  • The 25-34 age group experienced a nearly fourfold spike in alcohol-related deaths, while liver cancer emerged as the leading cause of alcohol-related cancer deaths with 7,408 fatalities in 2021.
  • Despite alcohol being classified as a carcinogen since 1987, only 45% of Americans recognize the cancer risk compared to 89% who understand tobacco's link to cancer.

Porton Advanced Accelerates Development of Innovative Cell Therapies for Solid Tumors with Key Partnerships

CAR-TOncology
  • Porton Advanced's CDMO services have enabled Tasly Pharmaceutical's dual-targeting CAR-T therapy for recurrent glioblastoma to receive IND approval from China's NMPA, demonstrating the effectiveness of their end-to-end manufacturing platform.
  • The company has established a new partnership with Hualong Biological to accelerate the development of Multi-Activated T Cell (MATC) therapy for solid tumors, leveraging Porton's regulatory expertise and manufacturing capabilities.
  • With 18 global IND approvals and specialized platforms for plasmids, viral vectors, and cell therapies, Porton Advanced is positioning itself as a leading CDMO in the advanced therapy medicinal products (ATMPs) sector.

Bayer Secures FDA Approval for Nubeqa in Metastatic Prostate Cancer, Targeting €3 Billion Peak Sales

OncologyDrug Approval
  • Bayer received FDA approval for Nubeqa (darolutamide) in combination with docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer, expanding beyond its initial non-metastatic indication.
  • The ARASENS trial demonstrated a 33% reduction in death risk when Nubeqa was added to standard androgen deprivation therapy plus docetaxel compared to placebo.
  • Bayer has tripled its peak sales forecast for Nubeqa from €1 billion to €3 billion following positive clinical data in the metastatic setting.
  • The approval positions Nubeqa to compete directly with established androgen receptor inhibitors Xtandi and Erleada in the advanced prostate cancer market.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy